Raymond E. Cabillot Sells 1,200 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 1,200 shares of Pro-Dex stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $47.76, for a total transaction of $57,312.00. Following the sale, the director now owns 359,646 shares of the company’s stock, valued at approximately $17,176,692.96. The trade was a 0.33 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Pro-Dex Stock Up 0.7 %

Shares of PDEX opened at $45.30 on Thursday. Pro-Dex, Inc. has a 1 year low of $16.18 and a 1 year high of $59.60. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.41 and a quick ratio of 1.94. The stock has a 50 day simple moving average of $48.12 and a two-hundred day simple moving average of $32.49. The firm has a market cap of $147.63 million, a P/E ratio of 29.42 and a beta of 0.56.

Analyst Ratings Changes

PDEX has been the topic of several research reports. Ascendiant Capital Markets raised their price objective on shares of Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, November 11th. StockNews.com raised Pro-Dex from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 14th.

Institutional Investors Weigh In On Pro-Dex

A number of institutional investors have recently made changes to their positions in PDEX. Dimensional Fund Advisors LP raised its position in Pro-Dex by 5.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock worth $1,238,000 after purchasing an additional 3,067 shares during the period. Renaissance Technologies LLC increased its stake in Pro-Dex by 7.9% in the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after purchasing an additional 900 shares during the period. Bard Associates Inc. increased its stake in shares of Pro-Dex by 17.6% in the third quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after buying an additional 2,031 shares during the period. FMR LLC raised its stake in shares of Pro-Dex by 34.9% during the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after acquiring an additional 1,028 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Pro-Dex by 9.1% during the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after purchasing an additional 2,296 shares during the period. Hedge funds and other institutional investors own 15.28% of the company’s stock.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.